Search Page

1

Cite

Share

COMT inhibition in the treatment of Parkinson's disease.

Ruottinen HM, Rinne UK. Ruottinen HM, et al. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. doi: 10.1007/pl00007743. J Neurol. 1998. PMID: 9808337 Review.

Cite

Share

2

Cite

Share

[18F]FDG-PET and whole-scalp MEG localization of epileptogenic cortex.

Lamusuo S, Forss N, Ruottinen HM, Bergman J, Mäkelä JP, Mervaala E, Solin O, Rinne JK, Ruotsalainen U, Ylinen A, Vapalahti M, Hari R, Rinne JO. Lamusuo S, et al. Among authors: ruottinen hm. Epilepsia. 1999 Jul;40(7):921-30. doi: 10.1111/j.1528-1157.1999.tb00799.x. Epilepsia. 1999. PMID: 10403216 Free article.

Cite

Share

3

Cite

Share

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.

Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO. Nurmi E, et al. Among authors: ruottinen hm. Mov Disord. 2001 Jul;16(4):608-15. doi: 10.1002/mds.1139. Mov Disord. 2001. PMID: 11481683

Cite

Share

4

Cite

Share

An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome.

Ruottinen HM, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O, Rinne JO. Ruottinen HM, et al. Neurology. 2000 Jan 25;54(2):502-4. doi: 10.1212/wnl.54.2.502. Neurology. 2000. PMID: 10668725

Cite

Share

5

Cite

Share

Comparison of [18F]FDG-PET, [99mTc]-HMPAO-SPECT, and [123I]-iomazenil-SPECT in localising the epileptogenic cortex.

Lamusuo S, Ruottinen HM, Knuuti J, Härkönen R, Ruotsalainen U, Bergman J, Haaparanta M, Solin O, Mervaala E, Nousiainen U, Jääskeläinen S, Ylinen A, Kälviäinen R, Rinne JK, Vapalahti M, Rinne JO. Lamusuo S, et al. Among authors: ruottinen hm. J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):743-8. doi: 10.1136/jnnp.63.6.743. J Neurol Neurosurg Psychiatry. 1997. PMID: 9416808 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis.

Rinne JO, Ruottinen HM, Någren K, Aberg LE, Santavuori P. Rinne JO, et al. Among authors: ruottinen hm. Neuropediatrics. 2002 Jun;33(3):138-41. doi: 10.1055/s-2002-33677. Neuropediatrics. 2002. PMID: 12200743

Cite

Share

7

Cite

Share

Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.

Trocóniz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO. Trocóniz IF, et al. Among authors: ruottinen hm. Clin Pharmacol Ther. 1998 Jul;64(1):106-16. doi: 10.1016/S0009-9236(98)90028-5. Clin Pharmacol Ther. 1998. PMID: 9695725 Clinical Trial.

Cite

Share

8

Cite

Share

Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.

Ruottinen HM, Rinne JO, Ruotsalainen UH, Bergman JR, Oikonen VJ, Haaparanta MT, Solin OH, Laihinen AO, Rinne UK. Ruottinen HM, et al. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):91-106. doi: 10.1007/BF02251225. J Neural Transm Park Dis Dement Sect. 1995. PMID: 9620057 Clinical Trial.

Cite

Share

9

Cite

Share

Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.

Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO. Nurmi E, et al. Among authors: ruottinen hm. Ann Neurol. 2000 Jun;47(6):804-8. Ann Neurol. 2000. PMID: 10852547

Cite

Share

10

Cite

Share

PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756.

Laihinen AO, Rinne JO, Ruottinen HM, Någren KA, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Rinne UK. Laihinen AO, et al. Among authors: ruottinen hm. J Nucl Med. 1994 Dec;35(12):1916-20. J Nucl Med. 1994. PMID: 7989969 Free article. Clinical Trial.

Cite

Share